3-氰基-4-乙氧基苯甲酸 | 258273-32-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-氰基-4-乙氧基苯甲酸
• 英文名称: 3-cyano-4-ethoxybenzoic acid
• 英文别名: 3-cyano-4-(ethyloxy)benzoic acid；4-ethoxy-3-cyanobenzoic acid
• CAS: 258273-32-4
• 化学式: C₁₀H₉NO₃
• mdl: MFCD09271828
• 分子量: 191.186
• InChiKey: PNGOHGRLVRKADR-UHFFFAOYSA-N

物化性质

• 沸点：
  370.1±27.0 °C(Predicted)
• 密度：
  1.27

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  70.3
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 危险性防范说明：
  P261,P280,P301+P312,P302+P352,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  3-氰基-4-乙氧基苯甲酸 在 吡啶 、 盐酸 、 草酰氯 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 、 N,N-二甲基甲酰胺 作用下， 以 1,4-二氧六环 、 二氯甲烷 、 甲苯 、 乙腈 为溶剂， 反应 7.5h， 生成 ethyl 3-[6-{5-[3-cyano-4-(ethyloxy)phenyl]-1,2,4-oxadiazol-3-yl}-5-methyl-3,4-dihydro-2(1H)-isoquinolinyl]propanoate
  参考文献：
  名称：

  Discovery of a Selective S1P₁ Receptor Agonist Efficacious at Low Oral Dose and Devoid of Effects on Heart Rate

  摘要：

  Gilenya (fingolimod, FTY720) was recently approved by the U.S. FDA for the treatment of patients with remitting relapsing multiple sclerosis (RRMS). It is a potent agonist of four of the five sphingosine 1-phosphate (SIP) G-protein-coupled receptors (S1P(1) and S1P(3-5)). It has been postulated that fingolimod's efficacy is due to S1P(1) agonism, while its cardiovascular side effects (transient bradycardia and hypertension) are due to S1P(3) agonism. We have discovered a series of selective S1P(1), agonists, which includes 3-[6- (5-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-5-methyl- 3,4-dihydro-2(1H)-isoquinolinyl]propanoate, 20, a potent, S1P(3)-sparing, orally active S1P(1) agonist. Compound 20 is as efficacious as fingolimod in a collagen-induced arthritis model and shows excellent pharmacokinetic properties preclinically. Importantly, the selectivity of 20 against S1P(3) is responsible for an absence of cardiovascular signal in telemetered rats, even at high dose levels.

  DOI：

  10.1021/ml2000214

文献信息

• [EN] ORGANIC COMPOUNDS<br/>[FR] COMPOSÉS ORGANIQUES
  申请人：AKAAL PHARMA PTY LTD

  公开号：WO2014063199A1

  公开（公告）日：2014-05-01

  Novel benzofuran derivatives are disclosed. The derivatives have S1P1 receptor activity and/or disease modifying activity and find use in the treatment of conditions or diseases associated with the immune, vascular and nervous systems in animals and/or humans

  揭示了新型苯并呋喃衍生物。这些衍生物具有S1P1受体活性和/或疾病修饰活性，并可用于治疗与动物和/或人类的免疫、血管和神经系统相关的疾病或症状。
• NOVEL MODULATORS OF SPHINGOSINE PHOSPHATE RECEPTORS
  申请人：Roberts Edward

  公开号：US20100010001A1

  公开（公告）日：2010-01-14

  Compounds that activate a sphingosine-1-phosphate receptor of the subtype 1 are provided. Certain compounds selectively activate the receptor subtype 1 in relation to the sphinogosine-4-phosphate receptor subtype 3. Uses and methods of inventive compounds for treatment of malconditions wherein activation, agonism, inhibition or antagonism of the S1P1 is medically indicated are provided.

  提供了激活1型鞘氨醇-1-磷酸受体的化合物。某些化合物在与鞘氨醇-4-磷酸受体亚型3相比，选择性地激活受体亚型1。提供了用于治疗需要医学上激活、激动、抑制或拮抗S1P1的恶性疾病的创新化合物的用途和方法。
• Phenyl-Oxetanyl-Derivatives
  申请人：Albert Rainer

  公开号：US20100261766A1

  公开（公告）日：2010-10-14

  Novel organic compounds are described and claimed which may in particular be useful in the treatment of diseases being triggered by the (human) autoimmune system.

  本发明描述和声明了一种新型有机化合物，特别适用于治疗由（人类）自身免疫系统引发的疾病。
• Modulators of sphingosine phosphate receptors
  申请人：Roberts Edward

  公开号：US08466183B2

  公开（公告）日：2013-06-18

  Compounds of the following generic structure are provided: Such compounds activate a sphingosine-I-phosphate receptor of the subtype 1 (S1P1), and have utility in the treatment of malconditions mediated by S1P1 activation. More specifically, such compounds are beneficial in the treatment of, for example, multiple sclerosis, transplant rejection and/or adult respiratory syndrome.

  提供以下通用结构的化合物：这些化合物激活亚型1的鞘氨醇-1-磷酸受体（S1P1），并且在治疗由S1P1激活介导的疾病方面具有用途。更具体地说，这些化合物对于治疗多发性硬化症、移植排斥和/或成人呼吸综合症等疾病具有益处。
• Novel modulators of sphingosine phosphate receptors
  申请人：THE SCRIPPS RESEARCH INSTITUTE

  公开号：EP2913326A1

  公开（公告）日：2015-09-02

  Compounds that activate a sphingosine-1-phosphate receptor of the subtype 1 are provided. Certain compounds selectively activate the receptor subtype 1 in relation to the sphinogosine-1-phosphate receptor subtype 3. Uses and methods of inventive compounds for treatment of malconditions wherein activation, agonism, inhibition or antagonism of the S1P1 is medically indicated are provided.

  本研究提供了能激活亚型 1 的鞘氨醇-1-磷酸受体的化合物。与鞘氨醇-1-磷酸受体亚型 3 相比，某些化合物可选择性地激活受体亚型 1。本发明提供了本发明化合物的用途和方法，用于治疗S1P1的激活、激动、抑制或拮抗在医学上有指示意义的不良病症。